Patients with advanced colorectal were enrolled in a molecular profiling program. Of 245 patients, at least one mutation was found in 64.5% patients, with TP53, RAS, APC and PIK3CA being the most common mutations. Right colon cancers harbor more molecular aberrations than left colon or rectal cancers. This difference may contribute to differential outcomes to anti-epidermal growth factor receptor therapy. Background: Molecular aberrations in KRAS, NRAS, BRAF, and PIK3CA have been well-described in advanced colorectal cancer. The incidences of other mutations are less known. We report results of molecular profiling of advanced colorectal cancer in an academic cancer center. Patients and Methods: Patients with advanced colorectal were enrolled in an institution-wide molecular profiling program. Profiling was performed on formalin-fixed paraffin embedded archival tissues using a customized MassArray panel (23 genes, 279 mutations) or the Illumina MiSeq TruSeq Cancer Panel (48 genes, 212 amplicons, ! 500Â coverage) in a Clinical Laboratory Improvement Amendments-certified laboratory. PTEN was determined by immunohistochemistry. Results: From March 2012 to April 2014, 245 patients were enrolled. At least one mutation was found in 54% (97/178) and 91% (61/67) of patients using MassArray or MiSeq platforms, respectively (P < .01). Of all patients, KRAS G12/13 mutation was identified in 39%, and non-G12/13 KRAS, BRAF, or NRAS mutations were present in 9%, 6%, and 4%, respectively. Other common mutations included TP53 (68.7%), APC (41.8%), and PIK3CA (13.5%). Co-mutation with KRAS, NRAS, or BRAF was found in 75% of patients with PIK3CA mutation. Of 106 patients with known PTEN immunohistochemistry status, 16% were negative. A higher average number of mutations were observed in right versus left colorectal cancer (P < .01), with 13 of 14 BRAF mutations located in right colon cancer. Conclusion: Mutations are common in advanced colorectal cancer. Right colon cancers harbor more genetic aberrations than left colon or rectal cancers. These aberrations may contribute to differential outcomes to anti-epidermal growth factor receptor therapy among patients with right colon, left colon, or rectal cancers.
Introduction
Colorectal cancer accounts for 9% of all cancer incidences and is the third most common cause of cancer-related death in the world. 1 With improved understanding of the pathobiology of colorectal cancer, molecular characterization has become an essential part in the management of colorectal cancer. Mutations in RAS (KRAS or NRAS ) are known predictive markers for lack of response, [2] [3] [4] whereas BRAF mutations confer poorer prognosis and resistance to anti-epidermal growth factor receptor (EGFR) therapy given beyond first-line treatment. 5 PIK3CA mutation may predict beneficial effect for adjuvant aspirin therapy and for non-responsiveness to anti-EGFR therapy. 6, 7 Traditionally, these mutational analyses are performed through sequencing of individual genes. However, patients frequently harbor multiple driver or passenger somatic mutations that confer growth advantage and positive selection. Thus, information of single gene(s) can no longer meet clinical needs as our knowledge in clinical significance of genomic aberrations continues to grow. Multiplex genetic testing and targeted next generation sequencing (NGS) allow simultaneous and more cost-effective testing of a large cohort of potentially actionable genetic aberrations using a relatively small amount of genetic materials. Although targeted NGS is not performed routinely yet, it has been available in selected academic cancer centers. [8] [9] [10] Here, we report our experience of molecular characterization of metastatic colorectal cancer through a center-wide molecular profiling effort.
Patients and Methods
Patients with histologically confirmed metastatic colorectal cancer were eligible if they were ! 18 years, Eastern Cooperative Oncology Group performance status 1 and had available formalin-fixed paraffin-embedded archival tumor tissues.
Details of the genomic assays have been described in detail elsewhere. 8 Briefly, the most recent archival tissue, either from the primary tumor or a metastatic site, was reviewed for tumor cellularity. DNA from tumor tissues was extracted using QIAmp DNA formalin-fixed paraffin-embedded Tissue kit (Qiagen, Germantown, MD) after de-paraffinization and proteinase K treatment. DNA was also extracted from a peripheral blood sample using either standard manual phenol/chloroform methods or automated extraction (MagAttract DNA Mini M48 Kit, Qiagen, Germantown, MD). All genomic assays were performed in a College of American Pathologists accredited and Clinical Laboratory Improvement Amendment certified laboratory. Initially, molecular profiling was performed using a customized recurrent mutation multiplex genotyping panel on a matrix-assisted laser desorption/ionization timeof-flight mass spectrometry platform (MassArray; Agena Bioscience, San Diego, CA). The panel was rationally developed based on the available systemic treatments and investigational agents at that time. It consisted of 24 multiplexed assays, and could detect 279 mutations in 23 oncogenes.
From April 2013, the TruSeq Amplicon Cancer Panel on the MiSeq sequencer (Illumina, San Diego, CA), was introduced and was the platform of choice when applicable. The TruSeq Amplicon Cancer Panel covered 212 amplicons in 48 cancer-associated genes.
Immunohistochemistry for PTEN was performed using rabbit monoclonal Ab 138G6 (Cell Signaling Technology, Danvers, MA) on Dako platform using a dilution of 1:50 and Flexþ30 protocol. An H-score of 50 or less was considered to be PTEN-deficient.
Descriptive statistics were used to summarize patient demographics and tumor characteristics. Comparison between 2 platforms, as well as subgroup comparison among right colon (cecum to transverse colon), left colon (splenic flexture to rectosigmoid), and rectal cancer were performed using the c 2 test.
Differences with a P-value of < .05 were considered to be statistically significant. Survival analysis was performed by the KaplanMeier method and compared with log-rank tests. Overall survival (OS) was defined as the time from diagnosis of advanced colorectal cancer to death from any cause. Patients for whom death was not documented were censored at the date of the most recent contact.
Results
From March 2012 to April 2014, 245 consecutive patients with metastatic colorectal cancer were enrolled, and tumor tissues from these patients were successfully molecularly characterized. Patient Table 1 . One or more mutations were found in 54% (97/178) and 91% (61/67) of patients using the MassArray and MiSeq platforms, respectively (P < .01).
Frequencies of the more common mutations were summarized in Figure 1 . The most frequent mutations were TP53 (68.7%), followed by KRAS (47.9%) and APC (41.8%). Less common mutations included PIK3CA (13.5%), FBXW7 (8.9%), SMAD4 (7.5%), BRAF (5.7%), NRAS(4.5%), and about 1% for CTNNB1. Infrequent mutations (< 1%) included ERBB2, FGFR3, EGFR, ERBB4, RB1, and IDH1. Although PTEN mutation was rare, a loss of PTEN expression was observed in 17 (16%) of 106 patients.
Among 245 patients, 58% harbored KRAS, NRAS, or BRAF mutations ( Figure 2 ). KRAS mutations outside of codons 12/13 were found in 9% of all patients. Although KRAS, NRAS, and BRAF mutations are mutually exclusive, co-mutations with other genes were common. The mutation pattern for each patient is shown in Figure 3 . PIK3CA and FBXW7 mutations were closely related to KRAS mutation, as 75% of patients with PIK3CA mutations also carried a KRAS (21/33), BRAF (3/33), or NRAS (1/33) mutation. Three of the 5 subjects with FBXW7 mutation carried a co-mutation with KRAS.
Mutations in Right Colon, Left Colon, and Rectal Colorectal Cancer
There was no difference in age, gender, and pathology grade among patients with right colon, left colon, or rectal cancer. There was no difference in proportion of cases tested by 2 platforms across 3 anatomic sites (Table 2) . However, the average numbers of mutations were significantly higher in right colon cancers than those in left colon cancers for both MassArray and MiSeq platforms (MassArray, 0.92 vs. 0.56; MiSeq, 3.25 vs. 1.86; P < .05). The frequency of KRAS or NRAS mutations was similar among these 3 anatomic sites, whereas BRAF mutation was predominantly found in right colon tumors; 13 of 14 patients with BRAF mutations had right colon cancer, and only 1 of 14 had left colon cancer. Comparison for other mutations was either non-significant or not done owing to small number of occurrences.
The median OS for patients with right colon, left colon, and rectal cancer was 2.93 years, 4.47 years, and 4.84 years, respectively, significantly shorter in right colon cancer compared with left colon, and rectal cancer (P < .001) or with the latter 2 combined (P < .0001). The Kaplan-Meier estimate was shown in Figure 4 .
Mutations in Primary Tumors and Metastatic Tissues
Among the 245 patients enrolled, tumor tissues were from the primary tumor for 162 patients (MassArray 120; MiSeq 42) and from metastatic sites for 83 patients (MassArray 58; MiSeq 25). There was no difference in frequency of mutation detected for TP53, KRAS, APC, or PIK3CA ( Figure 5 ). However, SMAD4 (5/ 42) and BRAF (14/162) mutations were only detected in primary tumors, not metastatic sites.
Discussion
This paper reports our experience with molecular profiling of advanced colorectal cancer using customized panels developed and performed at an academic cancer center. Our results show that the most common somatic mutations in colorectal were TP53, KRAS, APC, PIK3CA, FBXW7, SMAD4, BRAF, and NRAS. The frequencies of these mutations were consistent with previous published data from The Cancer Genome Atlas Network.
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Targeted NGS is a powerful and relatively cost-efficient tool for concurrent analysis of a large panel of genetic aberrations with a small amount of tissue material. NGS has the advantage over traditional polymerase chain reaction for its ability to detect uncommon mutations and single nuclear polymorphism at low coverage. For example, non-G12/13 KRAS mutations were present in 9% of patients respectively. These mutations were likely to have clinical significance but they might not be routinely covered by polymerase chain reaction testing, which is still the preferred method in many clinical pathology laboratories. In other words, targeted NGS could detect an additional 9% of patients who might not respond to anti-EGFR therapy.
The median OS observed were 2.93 years, 4.47 years, and 4.84 years for patients with right colon, left colon, and rectal cancer, respectively. Our patient population was a highly selected population in that the majority of patients was enrolled following progression on at least one chemotherapeutic regimen, and had an Eastern Cooperative Oncology Group performance status 0 and 1. These factors likely explain the differences in OS from other studies. 12 Even in this selected population, patients with right colon cancer had significantly worse OS than those with cancers from rest of the colon. 13 There have been debates whether cancers rising from the right colon are distinct from those rising from the left colon or rectum. Anatomically, the right colon is derived from embryonic midgut, and is supplied by the superior mesenteric artery, whereas the left colon originates from embryonic hind gut and is supplied by the inferior mesenteric artery.
In terms of macro-environment, they differ in metabolism of glucose and other nutrients, concentrations of bile acid, and composition of bacterial population. 14, 15 Pathologically, right colon cancer more often contains mucinous or undifferentiated histology, displays pseudo-diploid karyotypes, and harbors more mismatch repair defect. Left colon and rectal cancers, on the other hand, are more uniformly aneupolid, and are mostly mismatch repair stable. 
a These mutations were only performed on MiSeq. b P < .05.
Retrospective analysis from randomized phase III studies suggest that right colon cancer is associated with a poorer survival than left colon or rectal cancer, and patients with right colon cancer may benefit more from initial treatment with bevacizumab, whereas those with left colon or rectal cancer derive more benefit from initial treatment with cetuximab. 12, [17] [18] [19] One possible explanation for this observed difference in treatment response is that there are different patterns of gene expression between right colon cancer and left colon or rectal cancer. 20 Data from The Cancer Genome Atlas
Network showed that most hypermutated colorectal cancers were located in the right colon. 11 A recently proposed classification system found that the consensus molecular subtype 1 (CMS1) was more commonly found in right colon cancer. CMS1 is characterized by hypermutation, microsatellite instability, and strong immune activation. 21 An analysis of 1319 patients who underwent surgical resection for colorectal cancer found that right colon cancer more often showed microstatellite instability and mutated KRAS and BRAF. 16 Another recent study found that right-sided colon cancer more commonly harbored BRAF mutation, microsatellite instability, being CIMP-high, and CMS1 and CMS3. 22 Similarly, patients with right colon cancer harbored more mutations, and over 90% BRAF mutations occurred in right colon cancer in our study. These molecular aberrations are associated with resistance to anti-EGFR therapy, 5 thus partially contribute to the observation that patients with left colon or rectal cancer derive more benefit from initial treatment with cetuximab. Therefore, selection of treatment should be based on anatomical sites, as well as molecular profiling. In this study, tumor tissues from either the primary or metastatic sites were allowed. The most recently available tissue was utilized for molecular analysis, assuming it would be the more clinically relevant sample. There was no difference in average frequency of mutations between primary and metastatic tissues, although comparison between matched tissues from the same patients was not done. It was noted that mutations of SMAD4 (5/42 vs. 0/25) and BRAF (14/162 vs. 0/83) were only detected in primary tumors but not in metastases. The concordance rates of KRAS and BRAF between matched primary tumors and metastases have been reported to be greater than 90%. 23, 24 However, there is at least another study reporting that BRAF mutations were significantly less frequently detected in metastatic tumors. 25 Vakiani et al reported that the BRAF mutation rate was 7.7% in primary tumors, but only 1.7% in metastases (P < .01). BRAF mutations confer inferior survival for patients with stage II/III colorectal cancer, 26 or those with advanced colorectal cancer. [27] [28] [29] It is possible that patients with BRAF mutations are less likely to undergo metastectomy or biopsy of metastatic disease. This selection bias may explain the low rate of BRAF mutation in metastatic tissues in our cohort. However, the significance of our finding is limited by the small number of metastatic tissues evaluated.
In conclusion, genomic aberrations are common in advanced colorectal cancer. Patients with right colon cancer carry more mutations than those with left colon or rectal cancer. These aberrations may contribute to differential outcomes to anti-EGFR therapy among patients with right colon, left colon, or rectal cancers.
Clinical Practice Points
Molecular profiling of advanced is common, with different platforms in use. Patients with right colon cancer have differential outcomes to anti-epidermal growth factor receptor therapy from other with left colon or rectal cancer. KRAS G12/13 mutation was identified in 39%, and non-G12/ 13 KRAS, BRAF, or NRAS mutations were present in 9%, 6%, and 4%, respectively. Other common mutations included TP53 (68.7%), APC (41.8%), and PIK3CA (13.5%). PTEN deficiency was detected in 16% patients. Right colon cancers harbor more molecular aberrations than left colon or rectal cancers. These aberrations may contribute to differential outcomes to anti-epidermal growth factor receptor therapy among patients with right colon, left colon, or rectal cancers.
